Identification of maturity-onset diabetes of the young through targeted next-generation sequencing in Thai patients with atypical diabetes in real-world practice
Abstract
Introduction: Maturity-onset diabetes of the young (MODY) is often misdiagnosed as either autoimmune type 1 diabetes (T1D) or polygenic type 2 diabetes (T2D), resulting in missed diagnosis and inappropriate treatment. Differentiating MODY from T2D is challenging in Asians with low body mass index (BMI) and strong family history. The clinical impact of genetic testing in a real-world case series of Thai patients with atypical diabetes is not well defined. In this study, we aim to evaluate the diagnostic yield and clinical implications of targeted gene panel testing at a specialized diabetes outpatient clinic in Bangkok.
Materials and methods: We performed next-generation sequencing analysis of 33 monogenic diabetes genes in Thai patients recruited in 2019-2025 who had atypical features of diabetes including age-at-diagnosis≤ 40 years, BMI ≤25 kg/m2, random plasma C-peptide levels ≥ 0.1 ng/mL after at least three years of clinically-diagnosed T1D, syndromic features such as organ abnormalities or non-classical T1D or T2D presentations.
Results: Of the 33 probands with atypical diabetes (age-at-diagnosis 34.4 ± 14.4 years, BMI 23.7 ± 3.3 kg/m2, insulin-treated 39.3%), genetic testing identified a pathogenic or likely pathogenic variant in 4 (12.1%) probands. Variants in GCK were the most frequent (n=2, 50.0%), followed by HNF1A (n=1, 25.0%), and HNF1B (n=1, 25.0%). Genetic diagnoses led to targeted therapies and identification of MODY cases among family members. The latter…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.